Comparison of Pap Smear and Colposcopy in Screening for Cervical Cancer in Patients with Secondary Immunodeficiency

Mojgan Karimi-zarchi¹, Leila Zanbagh², Alireza Shafii³, Shokouh Taghipour-Zahir⁴, Soraya Teimoori⁵, Pouria Yazdian-Anari⁶

¹ Gynecology Oncology Fellowship, Associate Professor, Gynecology Department, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
² Gynecologist, Gynecology Department, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
³ Immunologist, Associate Professor, Immunology Department, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran
⁴ Pathologist, Associate Professor, Pathology Department, Faculty of Medicine, Shahid Sadoughi University of Medical Science, Yazd, Iran
⁵ Medical Student, Young Researchers and Elites Club, Faculty of Medicine, Islamic Azad University, Yazd Branch, Yazd, Iran
⁶ Medical Student, Student Research Committee, Faculty of Medicine, Shahid Sadoughi University of Medical Sciences, Yazd, Iran

Type of article: Original

Abstract

Introduction: Cervical cancer is the second most common cancer among women worldwide. The sensitivity of conventional Pap smear in detecting cervical lesions before cervical cancer is 51%, which means the false negative value is 49%. The aim of this study was to compare two methods for screening for cervical cancer in patients with secondary immunodeficiency, i.e., the conventional Pap smear and colposcopy.

Methods: This cross-sectional study was conducted on 101 immunodeficient patients who were referred to the Gynecologic Clinic at Shahid Sadoughi Hospital in Yazd from March 2011 to August 2012. All patients underwent the Pap test, a colposcopy, and a cervical biopsy, with the latter being considered as the gold-standard test.

Results: The most frequency of immunodeficiency was noted among patients with rheumatoid arthritis (53.3%), and this was followed by patients who were undergoing chemotherapy (30.7%), patients with lupus erythematosus (12.9%), and patients with AIDS (3%). The sensitivity, specificity, positive predictive value, negative predictive value, and accuracy of the Pap smear were 18.2, 98.5, 71.3, and 72.2%, respectively. The respective values for colposcopy were 66.7, 98.9, 97.9, and 97%, respectively.

Conclusion: In this study the accuracy, sensitivity, specificity, and negative predictive values of colposcopy were higher than those for the Pap smear in detecting high-grade, cervical, pre-malignant lesions (cervical intraepithelial neoplasia: CIN ≥ 2). Therefore, an annual colposcopy is advised for secondary immunodeficient patients instead of a Pap smear.

Keywords: immunodeficiency, conventional Pap smear, colposcopy, cervical cancer, sensitivity, specificity

1. Introduction

Cervical cancer is the second most common cancer among women worldwide, and it is responsible for 275,000 deaths each year (1). Among all known types of cancer, the prospects for preventing or curing cervical cancer are among the best because it can be diagnosed early when it is still curable. About 80% of cervical cancer cases occur...
in developing countries, and it is the most common cause of death in women (2, 3). The Papanicolaou (Pap) test is the most common and cost-effective screening method for detecting cervical cancer, and it has been effective in reducing the prevalence of this cancer and the associated mortality rates among women (4). Since 1950, the Pap smear has decreased the rate of cervical cancer by as much as 79%, and it has decreased the mortality rate by 70% (5). However, the incidence of cervical cancer in patients who undergo frequent Pap smears is increasing (6). The sensitivity of the conventional Pap smear in detecting lesions before cervical cancer occurs is 51%, which means the false negative value of this method is 49% (7). The sensitivity and specificity of the Pap test in detecting high-grade lesions of cervical intraepithelial neoplasia (CIN II and CIN III) have been shown to be 55.4 and 96.8%, respectively (8). In a study performed in Iran, it was found that less than 2% of the patients with cervical cancer had undergone a Pap smear in the previous 10 years (9, 10). Human papilloma virus (HPV) is the main cause of cervical intraepithelial neoplasia (CIN) and cervical cancer. Some studies have shown that women infected with high-risk HPV have a higher rate of progression from CIN to cancer, with a 300-fold increase in the risk of high-grade disease (6, 11, 12). Usually, HPV infections are not persistent, but those that remain may be latent for many years. Most women who are exposed have no clinical signs, and the infection is finally suppressed or eliminated (6, 7). In other women, low-grade cervical lesions occur, but, for the most part, they regress spontaneously. In many cases, the infection will clear in 9 to 15 months (6, 13). In a limited number of women who are exposed to HPV, persistent infection occurs that may progress to CIN (6, 7). In recent years, the use of prophylactic HPV vaccination has been initiated, but such vaccinations are not used in Iran, so we do not have the benefit of its effective role in decreasing the incidence of persistent HPV infection (6). The aim of this study was to compare two methods, i.e., Pap smear and colposcopy, for screening secondary immunodeficient patients for cervical cancer. These patients were referred to the Gynecologic Clinic at Shahid Sadoughi Hospital in Yazd from March 2011 to August 2012.

2. Material and Methods
This was a cross-sectional study that examined 101 immunodeficient patients who were referred to Shahid Sadoughi Hospital from March 2011 to August 2012. The criteria for inclusion in the study were being married, not being pregnant, and the age of 21 or within three years of the onset of sexual activity with no previous hysterectomy or previous histories of treating cervical lesions with a compromised immune system. The term 'immunodeficient patients' refers to immunosuppressed renal transplant recipients, patients known to be infected with HIV, patients being treated with immunosuppressive drugs for more than two months, such as cyclosporine, tacrolimus, sirolimus, mycofenolate mofetil, azathioprine, cyclophosphamide, thalidomide, etanercept, or corticosteroid with a dosage of 15 mg per day for three months, and patients taking chemotherapy for non-cervical cancer for more than two months. The exclusion criteria were patients whose Pap smear was not satisfactory. At the first visit, after providing informed consent, all of the patients underwent a Pap test, colposcopy, and cervical biopsy, and all of the results were recorded. The data were analyzed using SPSS version 17 (SPSS, Inc., Chicago, Illinois, USA). By using descriptive indices, we determined the sensitivity, specificity, positive and negative predictive value, and accuracy of each method, i.e., conventional Pap smear, colposcopy, and cervical biopsy, with the latter considered as the gold-standard test. The sample size was determined by considering 5% error and 80% sensitivity for colposcopy in detecting cervical intra-epithelial lesions, and, with the least error of 10%, the minimum size of the sample was determined to be 70 patients. However, we actually enrolled 101 patients in the study who met the inclusion criteria.

3. Results
In this study of 101 immunodeficient patients, the highest incidence of immunodeficiency (53.3%) was associated with rheumatoid arthritis. This was followed by chemotherapy (30.7%), patients with lupus erythematosus (12.9%), and AIDS (3%). Tables 1 and 2 provide the results of the Pap smears, colposcopies, and cervical biopsies.

### Table 1. Distribution of diagnostic results of colposcopy and biopsy cytology among the referred patients

| Results of biopsy and colposcopy | Biopsy | Colposcopy |
|----------------------------------|--------|-----------|
|                                  | n      | %         | n      | %         |
| Normal                           | 68     | 67.3      | 60     | 59.4      |
| CIN1                             | 28     | 27.7      | 36     | 35.6      |
| CIN2                             | 4      | 4         | 4      | 4         |
| CIN3                             | 1      | 1         | 1      | 1         |
| Total                            | 101    | 100       | 101    | 100       |

1: Cervical intraepithelial neoplasia
Table 2. Frequency of distribution of diagnostic results of cytology among the referred patients

| Results of cytology | Cytology | n | %  |
|---------------------|----------|---|----|
| LSIL                |          | 5 | 5  |
| ASC-H               |          | 3 | 3  |
| ASCUS               |          | 4 | 4  |
| Normal              |          | 89| 88 |
| Total               |          | 101| 100|

1: Low Grade Squamous Intraepithelial Lesion; 2: Atypical Squamous Cell Undetermined Significant

To achieve the results of sensitivity, specificity, positive and negative predictive value in Pap smear, once in general form and another time based on age and the type of immunodeficiency, data were analyzed (Tables 2-5). Sensitivity and specificity of colposcopy was not measurable based on age and the type of immunodeficiency because of existing one cell empty in table of sensitivity and specificity. In the 23 to 44 age group, we had three cases that had both positive colposcopy and positive biopsy. In the 45 to 78 age group, we had two cases with positive colposcopy, but no one had a positive biopsy. In the group I of immunodeficiency, we had two cases with positive colposcopy and positive biopsy, and, in the group II of immunodeficiency, we had three cases with positive colposcopy and just one with a positive biopsy.

Table 3. Comparison of the frequency distributions of diagnostic results of biopsy among the referred patients based on Pap smear test and colposcopy

| Results of Pap smear and colposcopy | Biopsy results | p-value |
|-------------------------------------|----------------|---------|
|                                     | Positive       | Negative|       |
| Pap smear                           | 6              | 1       | 0.002  |
| Positive                            | 27             | 67      |        |
| Negative                            | 33             | 68      |        |
| Total                               | 33             | 68      |        |
| Colposcopy                          | 4              | 1       | 0.000  |
| Positive                            | 2              | 94      |        |
| Negative                            | 6              | 95      |        |
| Total                               | 6              | 95      |        |

Table 4. Comparison of the frequency distribution of diagnostic results of biopsy and Pap smear test among the referred patients based on the type of immunodeficiency

| Results of Pap smear               | Biopsy results | p-value |
|------------------------------------|----------------|---------|
|                                    | Negative       | Positive|       |
| Group I immunodeficiency           | 1              | 3       | 0.064  |
| Positive                           | 44             | 19      |        |
| Negative                           | 45             | 22      |        |
| Total                              | 20             | 11      |        |
| Group II immunodeficiency          | 0              | 3       | 0.014  |
| Positive                           | 20             | 8       |        |
| Negative                           | 20             | 11      |        |
| Total                              | 20             | 11      |        |

Table 5. Comparison of the frequency distribution of diagnostic results of biopsy among the referred patients based on age groups and Pap smear

| Results of Pap smear (grouped by age) | Biopsy results | p-value |
|---------------------------------------|----------------|---------|
|                                      | Positive       | Negative|       |
| 23-44 year                            | 5              | 0       | 0.001  |
| Positive                              | 18             | 43      |        |
| Negative                              | 23             | 43      |        |
| Total                                 | 10             | 25      |        |
| 45-78 year                            | 1              | 1       | 0.490  |
| Positive                              | 9              | 24      |        |
| Negative                              | 10             | 25      |        |
Sensitivity and specificity 18.2% (CI: 12.6-24.6), 98.5% (CI: 92.5-100) and positive and negative predictive value of Pap test in general were 85.7 and 71.3%, respectively. The precision of the Pap smear was 72.2%. Sensitivity and specificity of colposcopy were 66.7% (CI: 60.7-72.7) and 98.94% (CI: 92.94-100), respectively, and the positive and negative predictive values of colposcopy were 80 and 97.9%, respectively. In general, the accuracy of colposcopy was calculated as 97%. Sensitivity and specificity of Pap smear in the 23-44 age group (fertility ages) were 21.7% (CI: 15.7-27.7) and 100%, respectively, and the positive and negative predictive values were 100 and 70.5%, respectively (table 3). We divided the immunodeficient patients into two groups, as shown in Table 4. Group I consisted of patients with systemic lupus erythematosus or rheumatoid arthritis, as well as renal transplant recipients who had been treated with immunosuppressive drugs for more than two months, e.g., cyclosporine, tacrolimus, sirolimus, mycofenolate mofetil, azathioprine, cyclophosphamide, thalidomide, etanercept, and corticosteroid with dosages of 15 mg per day for three months. Group II included patients with different types of tumors, such as breast cancer or lymphoma, who had undergone chemotherapy for more than two months. Sensitivity and specificity of Pap smear in group I of immunodeficiency patients, including patients with systemic lupus erythematosus and rheumatoid arthritis as well as renal transplant recipients and those with multiple sclerosis 13.6% (CI: 7.6-19.6) and 97.8% (CI: 91.8-100) respectively. Positive and negative predictive were 75% and 69.8%, respectively. Group II immunodeficiency patients included patients receiving chemotherapy, and the sensitivity and specificity of their Pap test were 27.3% (CI: 33.3-21.3) and 100%, respectively, and their positive and negative predictive values were 100 and 71.4%, respectively. The accuracies of the Pap smears in groups I and II of immunodeficient patients were calculated as 70.14 and 74.19%, respectively. We had four patients who were Atypical Squamous Cell Undetermined Significant (ASCUS) in the Pap test and three of them were CIN1 in colposcopy, while only one of them was confirm by biopsy as CIN1. According to Table 6, among the 101 immunodeficient patients, the frequency distribution of HPV infection was 21.8%, and the most frequency was related to HPV16 subtype of HPV, which was 17.8%.

**Table 6.** Frequency distribution of HPV infection among referred patients

| Result of HPV test | n | % |
|--------------------|---|---|
| Negative for HPV    | 79 | 78.2 |
| Positive cases      |   |   |
| HPV6               | 2 | 2 |
| HPV16              | 18 | 17.8 |
| HPV18              | 1 | 1 |
| HPV34              | 1 | 1 |
| Total positive cases| 22 | 21.8 |

**4. Discussion**

In developing countries, cervical cancer, which is preventable, is one of the most common causes of death in women. Several meta-analysis studies have shown that the sensitivity and specificity of cervical cytology is relatively low, since sensitivity is 30-87% and specificity is 100 to 86% (14). In this study, sensitivity, specificity, and the positive and negative predictive values test of Pap smear were determined to be 18.2, 98.5, 85.7, and 71.3%, respectively. Sensitivity, specificity, and the positive and negative predictive values of colposcopy were calculated as 66.7, 98.94, 80, and 97.9%, respectively. An abnormal Pap smear is an indication for colposcopy, endocervical curettage, and cervical biopsy for detecting cervical cancer (15). In this study we had four patients who were ASCUS in Pap test and three of them were CIN1 in colposcopy, while only one of them was confirmed by biopsy as CIN1. According to Table 6, among the 101 immunodeficient patients, the frequency distribution of HPV infection was 21.8%, and the most frequent was related to HPV16 subtype of HPV, which was 17.8%.
beneficial than other preventive cares. This study showed that 20.3% of HIV patients had abnormal Pap smears, and 10.7% of them had abnormal colposcopy. The results of this study suggest that colposcopy should be considered as the routine screening for these patients (21). While, in this study, abnormal Pap smear was 7% and abnormal colposcopy was 5%. In the study of Maiman et al. (1998) in Colombia on 248 HIV-infected women, the sensitivity and specificity of colposcopy for all CIN grades were 80 and 29%, respectively, and, for high-grade CIN, they were 83 and 27%, respectively (22). In this study, the positive colposcopy included CIN2 and higher, and, because of the inadequate sample, we could not calculate the sensitivity and specificity in each grade of CIN separately as was done in the previous study. In Vanuatu, in a pilot study of 496 women, cytology and visual inspection were evaluated as screening tests for detection of CIN2 or worse (CIN2+). Using Lugol’s iodine for the detection of CIN2+ on biopsy, the sensitivity of Visual Inspection was 0.63. The specificity was 32%, and the positive predictive value was 0.09. Sensitivity was 0.99 and specificity was 0.77 for HSIL cytology, while the positive predictive value was 0.88. Compared to visual inspection, HSIL cytology was much more sensitive, and its positive predictive value for CIN2+ was significantly greater (p < 0.01) (23). A Japanese study used low-grade squamous intraepithelial lesion as the cut-off point, and there was a 94.7% sensitivity for the detection of cervical cancer (24). Due to the use of different reference tests and different target groups, various studies have reported different accuracy values for conventional cytology (8, 25). Even so, sensitivity was in the range of 50 to 80%, while specificity was in the range of 70 to 90% (26). In a cohort study, Anderson et al. examined the accuracy of the Pap test among women who had HIV infections as well as women at high risk for such infections. They concluded that, for these two groups of women, there was significant agreement between the cytologic findings and the colposcopic and histologic findings. Despite having normal cytologic findings, a few of the HIV-infected women had cervical intraepithelial neoplasia. Among these women, Pap screenings would have detected cytologic abnormalities in 95% of these women within one year. These findings do not support the routine use of colposcopy in all HIV-infected women (27). Studies in the USA have shown that women in the 29-30 age group who live in areas where the prevalence of HPV and HIV is high have a higher risk of having cervical cancer. Cervical cancer is invasive, but it also is preventable if special screening is conducted for HIV-infected women (28). The results of a review study showed that many gynecologists in health organizations consider neither special screening for cervical cancer for HIV-infected women nor the function of the immune system, such as CD4 lymphocyte (29). Canada is one of the many countries in the world in which colposcopy is used extensively for the routine screening of HIV-infected women. However, for ethical reasons and because of the high cost, this method is not routinely used to date. In Canada, routine screening is done every six months using the Pap smear and follow-up tests if the patients have HIV (30). In the USA, it is suggested that, even when the Pap smear is normal, patients should repeat the Pap smear every three months (31-33). Leibenson et al. studied 84 HIV-infected women, and their results showed that HIV-infected and immunocompromised women are more vulnerable to cervical cancer, but special programs for screening of these patients have yet to be implemented (32). It seems that the rate of persistent HPV in these patients is higher than in the general population because their immune systems are compromised, making them vulnerable to pre-malignant lesions.

5. Conclusions
In this study, colposcopy produced higher levels of accuracy, sensitivity, specificity, and negative predictive value than Pap smear in detecting high-grade, cervical, pre-malignant lesions (CIN≥2). Since cervical cancer is the most common gynecological cancer in developing countries and since the accuracy of the Pap smear was low in this study, there is a clear need for a method that can provide an early diagnosis of cervical cancer. For that reason, we recommend that secondary immunodeficient patients have an annual colposcopy instead of a Pap smear.

Acknowledgments:
The authors thank the Shahid Sadughi Hospital for supporting the study.

Conflict of Interest:
There is no conflict of interest to be declared.

Authors' contributions:
All authors contributed to this project and article equally. All authors read and approved the final manuscript.
References

1) de Freitas AC, Coimbra EC, Leitão MdCG. Molecular targets of HPV oncoproteins: Potential biomarkers for cervical carcinogenesis. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2014;1845(2):91-103, doi: 10.1016/j.bbr.2013.12.004. PMID: 24388872.

2) Spensley S, Hunter RD, Livsey JE, Swindell R, Davidson SE. Clinical outcome for chemoradiotherapy in carcinoma of the cervix. Clinical oncology. 2009;21(1):49-55, doi: 10.1016/j.clon.2008.10.014. PMID: 19081712.

3) Bueno CT, Silva CMDd, Barcellos RB, Silva Jd, Santos CRd, Menezes JES, et al. Association between cervical lesion grade and micronucleus frequency in the Papanicolaou test. Genetics and molecular biology. 2014;37(3):496-9, doi: 10.1590/S1415-47522014000400004. PMID: 25249771, PMCid: PMC4171763.

4) Peirson L, Fitzpatrick-Lewis D, Ciliska D, Warren R. Screening for cervical cancer: a systematic review and meta-analysis. Syst Rev. 2013;2(35):1-14, doi: 10.1186/2046-4053-2-35.

5) Ries L, Melbert D, Krapcho M, Stinchcomb D, Howlader N, Horner M, et al. SEER cancer statistics review, 1975-2005. Bethesda, MD: National Cancer Institute. 2008:1975-2005.

6) Berek JS, Hacker NF. Practical Gynecologic Oncology: Lippincott Williams & Wilkins; 2000.

7) Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM, et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. The New England journal of medicine. 1992;327(18):1272-8, doi: 10.1056/NEJM199210293271804. PMID: 1328880.

8) Mayrand MH, Duarte-Franco E, Rodrigues I, Walter SD, Hanley J, Ferencyz A, et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. The New England journal of medicine. 2007;357(16):1579-88, doi: 10.1056/NEJMoa071430. PMID: 17942871.

9) Zarchi MK, Binesh F, Kazemi Z, Teimoori S, Soltani HR, Chiti Z. Value of Colposcopy in the Early Diagnosis of Cervical Cancer in Patients with Abnormal Pap Smears at Shahid Sadoughi Hospital, Yazd. Asian Pacific Journal of Cancer Prevention. 2011;12:3439-41.

10) Karimi Zarchi M, Akhavan A, Fallahzadeh H, Gholami H, Dehghani A, Teimoori S. Outcome of cervical cancer in Iranian patients according to tumor histology, stage of disease and therapy. Asian Pacific journal of cancer prevention : APJCP. 2010;11(5):1289-91. PMID: 21198279.

11) Ley C, Bauer HM, Reingold A, Schiffman MH, Chambers JC, Tashiro CJ, et al. Determinants of genital human papillomavirus infection in young women. Journal of the National Cancer Institute. 1991;83(4):997-1003, http://dx.doi.org/10.1093/jnci/83.14.997. PMID: 1649312.

12) Bernard E, Pons-Salort M, Favre M, Heard I, Delarocque-Astagneau E, Guillemot D, et al. Comparing human papillomavirus prevalences in women with normal cytology or invasive cervical cancer to rank genotypes according to their oncogenic potential: a meta-analysis of observational studies. BMC infectious diseases. 2013;13(1):1-11, doi: 10.1186/1471-2334-13-373. PMID: 23941096, PMCid: PMC3751808.

13) Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. The New England journal of medicine. 1998;338(7):423-8. doi: 10.1056/NEJM199802123380703, PMID: 9459645.

14) Nanda K, McCrory DC, Myers ER, Bastian LA, Hasselblad V, Hickey JD, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytopathic abnormalities: a systematic review. Annals of internal medicine. 2000;132(10):810-9, doi: 10.1056/NEJM1999802123380703. PMID: 9459645.

15) Novak E, Berek JS. Berek & Novak's gynecology: Lippincott Williams & Wilkins; 2007.

16) Alloub MI, Barr BB, McLaren KM, Smith IW, Bunney MH, Smart GE. Human papillomavirus infection and cervical intraepithelial neoplasia in women with renal allografts. BMJ (Clinical research ed). 1989;298(6667):153-6, doi: 10.1136/bmj.298.6667.153.

17) Cordiner J, Sharp F, Briggs J. Cervical intraepithelial neoplasia in immunosuppressed women after renal transplantation. Scottish medical journal. 1980;25(4):275-7. PMID: 7010590.

18) Branca M, Rossi E, Alderisio M, Migliore G, Morosini PL, Vecchione A, et al. Performance of cytology and colposcopy in diagnosis of cervical intraepithelial neoplasia (CIN) in HIV-positive and HIV-negative women. Cytopathology. 2001;12(2):84-93, doi: 10.1046/j.1365-2303.2001.00299.x. PMID: 11284952.

19) Mitchell MF, Schottenfeld D, Tortolero-Luna G, Cantor SB, Richards-Kortum R. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstetrics and gynecology. 1998;91(4):626-31, doi: 10.1016/S0029-7844(98)00006-4.

20) Gaudette LA, Gao RN, Freitag S, Wideman M. Cancer incidence by ethnic group in the Northwest Territories (NWT) 1969-1988. Health reports. 1993;5(1):23-32. PMID: 8334235.

21) Yamada R, Sasagawa T, Kirumbi LW, Kingoro A, Karanja DK, Kiptoo M, et al. Human papillomavirus infection and cervical abnormalities in Nairobi, Kenya, an area with a high prevalence of human
immunodeficiency virus infection. Journal of medical virology. 2008;80(5):847-55, doi: 10.1002/jmv.21170. PMid: 18360898.

22) Maiman M, Fruchter RG, Sedlis A, Feldman J, Chen P, Burk RD, et al. Prevalence, risk factors, and accuracy of cytologic screening for cervical intraepithelial neoplasia in women with the human immunodeficiency virus. Gynecologic oncology. 1998;68(3):233-9, doi: 10.1006/gyno.1998.4938. PMid: 9570972.

23) McAdam M, Sakita J, Tarivonda L, Pang J, Frazer IH. Evaluation of a cervical cancer screening program based on HPV testing and LLETZ excision in a low resource setting. PloS one. 2010;5(10):e13266, doi: 10.1371/journal.pone.0013266. PMid: 20949059, PMCid: PMC2951361

24) Yoshida Y, Sato S, Okamura C, Nishino Y, Yajima A. Evaluating the accuracy of uterine cancer screening with the regional cancer registration system. Acta cytologica. 2001;45(2):157-62, doi: 10.1159/000327270. PMid: 11284299

25) Cuzick J, Clavel C, Petry KU, Meijer CJ, Hoyer H, Ratnam S, et al. Overview of the European and North American studies on HPV testing in primary cervical cancer screening. International journal of cancer Journal international du cancer. 2006;119(5):1095-101, doi: 10.1002/ijc.21955.

26) Hamashima C, Aoki D, Miyagi E, Saito E, Nakayama T, Sagawa M, et al. The Japanese guideline for cervical cancer screening. Japanese journal of clinical oncology. 2010:hyq036.

27) Anderson JR, Paramsothy P, Heilig C, Jamieson DJ, Shah K, Duerr A. Accuracy of Papanicolaou test among HIV-infected women. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006;42(4):562-8, doi: 10.1086/499357. PMid: 16421802.

28) Stephens PC, Sloboda Z, Grey S, Stephens R, Hammond A, Hawthorne R, et al. Is the receptivity of substance abuse prevention programming affected by students' perceptions of the instructor? Health education & behavior : the official publication of the Society for Public Health Education. 2009;36(4):724-45, doi: 10.1177/1090198107304388. PMid: 18809689

29) Anastos K, Denenberg R, Solomon L. Human immunodeficiency virus infection in women. Medical Clinics of North America. 1997;81(2):533-53, doi: 10.1016/S0025-7125(05)70530-7.

30) Hankins CA, Lamont JA, Handle M. Cervicovaginal screening in women with HIV infection: a need for increased vigilance? CMAJ: Canadian Medical Association Journal. 1994;150(5):681. PMid:8313287, PMCid: PMC1486337

31) Palefsky JM, Minkoff H, Kalish LA, Levine A, Sacks HS, Garcia P, et al. Cervicovaginal human papillomavirus infection in human immunodeficiency virus-1 (HIV)-positive and high-risk HIV-negative women. Journal of the National Cancer Institute. 1999;91(3):226-36, doi: 10.1093/jnci/91.3.226. PMid: 10037100

32) Leibenson L, Banani S, Bor A, Meirovitz M, Avni YS, Singer D, et al. The prevalence of human papillomavirus and cervical cytology abnormalities in women infected with human immunodeficiency virus in southern Israel. The Israel Medical Association journal : IMAJ. 2011;13(1):34-8. PMid:21446234